chPD1-Dap10 CAR-T cells

chPD1-Dap10 CAR-T cells are an experimental chimeric antigen receptor (CAR) T-cell immunotherapy developed in academic research settings, primarily by Amorette E. Barber at Longwood University. The construct features a chimeric PD-1 receptor comprising the extracellular domain of the PD-1 receptor fused to the Dap10 costimulatory domain and the CD3ζ signaling domain. Unlike traditional CARs that target tumor-associated antigens, this therapy utilizes the PD-1 extracellular domain to recognize PD-1 ligands (PD-L1 and PD-L2) frequently overexpressed on various solid tumors and lymphomas. The inclusion of the Dap10 domain promotes a pro-inflammatory cytokine profile (secreting IFNγ, TNFα, and IL-2 without significant anti-inflammatory IL-10) and induces a central/memory precursor T-cell phenotype, leading to enhanced in vivo persistence and anti-tumor efficacy compared to other costimulatory domains like CD28.

Other names

chPD1-Dap10 CAR-TchPD-1-Dap10 CAR-TchPD 1-Dap10 CAR-Tchimeric PD1-Dap10 T cells